Novel 2-Nitroimidazole and Imidazooxazole Derivatives and their Activity against Trypanosoma cruzi and Mycobacterium tuberculosis.


Journal

Medicinal chemistry (Shariqah (United Arab Emirates))
ISSN: 1875-6638
Titre abrégé: Med Chem
Pays: Netherlands
ID NLM: 101240303

Informations de publication

Date de publication:
2022
Historique:
received: 14 07 2021
revised: 10 09 2021
accepted: 15 09 2021
pubmed: 18 11 2021
medline: 13 4 2022
entrez: 17 11 2021
Statut: ppublish

Résumé

Tuberculosis (TB) is one of the top ten causes of death worldwide, while Chagas disease (CD) is the parasitic disease that kills the largest number of people in the Americas. TB is the leading cause of death for patients with AIDS; it kills 1.5 million people and causes 10 million new cases every year. The lack of newly developed chemotherapeutic agents and insufficient access to health care services for a diagnosis increase the incidence of multidrug-resistant TB (MDRTB) cases. Although CD was identified in 1909, the chronic stages of the disease still lack adequate treatment. The purpose of this work was to design and synthesize two new series of 2-nitroimidazole 5a-e and imidazooxazoles 6a-e with 1H-1,2,3-triazolil nucleus and evaluate their activities against Tc and Mycobacterium tuberculosis (Mtb). Two series of five compounds were synthesized in a 3 or 4-step route in moderated yields, and their structures were confirmed by NMR spectral data analyses. The in vitro antitrypanosomal evaluation of products was carried out in an intracellular model using L929 cell line infected with trypomastigotes and amastigote forms of Tc of β-galactosidase-transfected Tulahuen strain. Their antimycobacterial activity was evaluated against Mtb strain H37Rv. In general, 2-nitroimidazolic derivatives proved to be more potent in regard to antitrypanocidal and antimycobacterial activity. The non-cytotoxic 2-nitroimidazole derivative 5b was the most promising with a half maximum inhibitory concentration of 3.2 μM against Tc and a minimum inhibitory concentration of 65.3 μM against Mtb. Our study reinforced the importance of 2-nitroimidazole and 1H-1,2,3-triazole nuclei in antimicrobial activity. In addition, derivative 5b proved to be the most promising, presenting important activity against Tc and Mtb and could be used as a starting point for the development of new agents against these diseases.

Sections du résumé

BACKGROUND BACKGROUND
Tuberculosis (TB) is one of the top ten causes of death worldwide, while Chagas disease (CD) is the parasitic disease that kills the largest number of people in the Americas. TB is the leading cause of death for patients with AIDS; it kills 1.5 million people and causes 10 million new cases every year. The lack of newly developed chemotherapeutic agents and insufficient access to health care services for a diagnosis increase the incidence of multidrug-resistant TB (MDRTB) cases. Although CD was identified in 1909, the chronic stages of the disease still lack adequate treatment.
OBJECTIVE OBJECTIVE
The purpose of this work was to design and synthesize two new series of 2-nitroimidazole 5a-e and imidazooxazoles 6a-e with 1H-1,2,3-triazolil nucleus and evaluate their activities against Tc and Mycobacterium tuberculosis (Mtb).
METHODS METHODS
Two series of five compounds were synthesized in a 3 or 4-step route in moderated yields, and their structures were confirmed by NMR spectral data analyses. The in vitro antitrypanosomal evaluation of products was carried out in an intracellular model using L929 cell line infected with trypomastigotes and amastigote forms of Tc of β-galactosidase-transfected Tulahuen strain. Their antimycobacterial activity was evaluated against Mtb strain H37Rv.
RESULTS RESULTS
In general, 2-nitroimidazolic derivatives proved to be more potent in regard to antitrypanocidal and antimycobacterial activity. The non-cytotoxic 2-nitroimidazole derivative 5b was the most promising with a half maximum inhibitory concentration of 3.2 μM against Tc and a minimum inhibitory concentration of 65.3 μM against Mtb.
CONCLUSION CONCLUSIONS
Our study reinforced the importance of 2-nitroimidazole and 1H-1,2,3-triazole nuclei in antimicrobial activity. In addition, derivative 5b proved to be the most promising, presenting important activity against Tc and Mtb and could be used as a starting point for the development of new agents against these diseases.

Identifiants

pubmed: 34784878
pii: MC-EPUB-118866
doi: 10.2174/1573406418666211116144952
doi:

Substances chimiques

Antitubercular Agents 0
Nitroimidazoles 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

701-709

Subventions

Organisme : National Council for Scientific and Technological Development – CNPq
ID : PROEP 407852/2007-4
Organisme : Foundation for Research of the State of Rio de Janeiro (FAPERJ)
ID : 306193/2018-3
Organisme : MNCS, Research Productivity Fellowships from the CNPq
ID : E-26/202.805/2017

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Jessica V Faria (JV)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.
Pós-graduação em Química, Universidade Federal Fluminense - UFF, Campus do Valonguinho, Niterói, RJ, CEP 24020-150, Brazil.

Fernanda P Z Passos (FPZ)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Paulo H A da Costa (PHA)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Andressa P de Oliveira (AP)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Yasmin O D da Cruz (YODD)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Frederico S Castelo-Branco (FS)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Maria C S Lourenço (MCS)

Fundacao Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratorio de Bacteriologia e Bioensaios em Micobacterias, Rio de Janeiro, RJ, CEP 21045-900, Brazil.

Silvane M F Murta (SMF)

Instituto René Rachou, Fiocruz Minas Gerais, Belo Horizonte, MG, CEP 30190-002, Brazil.

Policarpo A S Junior (PAS)

Instituto René Rachou, Fiocruz Minas Gerais, Belo Horizonte, MG, CEP 30190-002, Brazil.

Alice M R Bernardino (AMR)

Pós-graduação em Química, Universidade Federal Fluminense - UFF, Campus do Valonguinho, Niterói, RJ, CEP 24020-150, Brazil.

Monica M Bastos (MM)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Nubia Boechat (N)

Departamento de Síntese de Farmacos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Manguinhos, Rio de Janeiro, RJ, CEP 21041-250, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH